Circulating Tumor Cells (CTC) Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH1184 | Last Updated On: Nov 03 2022 | Available Formats

> Circulating Tumor Cells (CTC) Market Expected to reach a high CAGR of 13.26% By 2029

Circulating Tumor Cells (CTC) Market is segmented By Technology (CTC Detection Technology, CTC Enrichment Technology), By Application (EMT Biomarkers Development, Tumorigenesis Research, Cancer Stem Cell, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2022-2029

circulating tumor cells (CTC) market size was valued at US$ 11,538.93 million in 2022 and is estimated to reach US$ 19,708.44 million by 2029, growing at a CAGR of 13.26% during the forecast period (2022-2029).

Circulating Tumor Cells (CTC) Market



Market CAGR


Segments Covered

By Product, By Technology, By Specimen, By Application, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Circulating tumor cells (CTCs) are cells that have shed into the vasculature or lymphatics from a primary tumor and are carried around the body in the blood circulation. CTCs constitute seeds for the subsequent growth of additional tumors in distant organs, a mechanism responsible for the vast majority of cancer-related deaths. The detection and analysis of CTCs can assist early patient prognoses and determine appropriate tailored treatments.

Market Dynamics

Rising prevalence rates of cancers such as breast cancer, lung cancer and more, increasing research and development, and improvements in CTC diagnostics technology are the major factors driving the global circulating tumor cells (CTC) market.

The rising technological advancements and increasing research and development are expected to drive the market’s growth.

The circulating tumor cells (CTC) market is driven by factors such as rising technological advancements, an increasing geriatric population, and improvements in CTC diagnostic and enrichment technology are expected to drive the CTC market. The market’s growth can also be attributed to the rising number of research and development, clinical trials, and conferences to increase awareness about the technology. Moreover, the availability of technologically advanced devices by key players is also expected to play a vital role in the market’s growth. Rising government funding and increasing healthcare expenditure to treat chronic diseases will boost market growth.

Another driving factor for the circulating tumor cells (CTC) market is the high adoption rate of CTC technology for diagnostic and guiding prognosis. Thus, increasing awareness about novel circulatory tumor cell technology among patients and hospitals will provide market players with better opportunities in the future. Various novel product launches and research studies contribute to the market’s growth. For instance, in Nov 2021, Menarini Silicon Biosystems, liquid biopsy technologies company, announced its commercial launch of CELLSEARCH, a laboratory-developed test for counting the circulating multiple myeloma cells (CMMC) from the blood. This assay provides early detection of disease and its progression in patients at risk.

High costs associated with circulating tumor cells (CTC) diagnostics are expected to hamper market growth.

The high cost of these systems and devices used for diagnosis and the guiding prognosis is the main factor responsible for restraining the market. The therapy takes much time, and there is an unavailability of commercialized products, which gradually increases the cost.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The circulating tumor cells (CTC) market has experienced huge losses due to COVID, as various research and clinical trials got postponed due to the increasing cases of COVID, leading to diverting all the attention towards COVID. Various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Jun 2021, Biocept Inc., a molecular diagnostic assay provider, announced its collaboration with Quest Diagnostics to provide lab testing services for Quest’s target selector NGS-based liquid biopsy that targets lung cancer.

Segment Analysis

The technology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The technology segment is the highest market holder in the global circulating tumor cells (CTC) market. Based on Technology, the global circulating tumor cells (CTC) market is segmented into CTC detection and enrichment technology and CTC Analysis. Circulating tumor cells differ from normal blood cells in morphology, gene expression, biophysical functions, and volume. All these factors lead to the development and commercialization of various CTC diagnosis devices. The most commonly used method for CTC diagnosis is immune-based detection, where specific antibodies are utilized to selectively bind the cell surface antigen. The tumor cells and blood cells express distinct cell surface markers and hence can be easily separated from circulatory cells.

The technology segment dominates the market due to the demand for CTC diagnostic devices and systems and rising global incidences of cancer. The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in Jun 2022, BioFluidica introduced its LiquidScan, a microfluidic chip that searches for any rare biomarker in the blood sample like cell-free DNA, circulating tumor cells (CTCs) or exosomes, particles naturally released from cells.

Geographical Analysis

North America holds the largest market share in the global circulating tumor cells (CTC) market.

North America dominates the global circulating tumor cells (CTC) market, primarily attributed to the rising number of people suffering from a variety of cancer. According to the World Health Organization report 2020, 2.3 million women were diagnosed with breast cancer, of which 685,000 deaths occurred globally.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market’s growth in this region. Advancement of technology in these systems and devices, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the circulating tumor cells (CTC) market.

Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Sep 2021, Thermo Fisher Scientific launched its applied biosystem QuantStudio Absolute Q digital PCR system, a fully integrated digital PCR system that will provide consistent and accurate results. This technology is used by biotech companies or research institutes for cancer-driving mutations monitoring in liquid biopsy and in cell therapy development; it quantifies gene inserts precisely.

Competitive Landscape

The circulatory tumor cells market is moderately competitive with local and global companies’ presence. QIAGEN N.V., Bio-Techne Corporation, Biocept Inc., Thermo Fisher Scientific, LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Precision Medicine Group, Fluxion Biosciences Inc., BioFluidica and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Jun 2022, Plus Therapeutics, Inc., a pharmaceutical company at a clinical stage that designs targeted radiotherapeutics for cancers and Biocept Inc., a molecular diagnostic assay and products provider, announced a multi-year agreement for the clinical trial of ReSPECT LM phase 1/2a dose of Rhenium-186 NanoLiposome for treating leptomeningeal metastases, cancer in membranes near the spinal cord.


Overview: Qiagen is a company that develops sample and assay technologies for molecular testing, diagnostics, and biopharma research. It was founded in 1984 and is headquartered in Hilden, Germany. Their products and services are being provided in around 25 countries.

Product Portfolio:

AdnaTest Breast Cancer: It provides the molecular characterization of the circulating tumor cells (CTCs).  As this works on the combination of combinations principle, it combines AdnaTest Breast Cancer Detect with the AdnaTest Breast Cancer Select. The AdnaTest is an immunomagnetic cell-selection system that is highly specific for enriching CTCs from the peripheral blood. Using RT-PCR, it detects gene expression associated with breast cancer in enriched tumor cells.

The global circulating tumor cells (CTC) market report would provide access to approx. 45+market data table, 40+figures and 200 (approximate) pages.

Trending Topics

Neuroendocrine Tumor Treatment

Tumor Ablation Market

miRNA Tools and Services Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!